Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma

A Lamarca1, A Vogel2

  • 1Department of Medical Oncology - OncoHealth Institute, Fundación Jiménez Díaz University Hospital, Madrid, Spain; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.

ESMO Open
|November 3, 2023
PubMed
Abstract

No abstract available in PubMed .